相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti et al.
CELLULAR IMMUNOLOGY (2019)
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
Benjamin Bian et al.
ONCOIMMUNOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
R. S. Herbst et al.
ANNALS OF ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
Luigi Cavanna et al.
Oncotarget (2019)
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
Francesco Passiglia et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam et al.
ANNALS OF ONCOLOGY (2018)
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
A. Russo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current PD-L1 immunohistochemistry for non-small cell lung cancer
Andreas H. Scheel et al.
JOURNAL OF THORACIC DISEASE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Hongshu Sui et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
Lidia Rita Corsini et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC
Hangjun Wang et al.
Oncotarget (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer
Reinhard Buttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer
Chao Li et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 IHC in NSCLC with a global and methodological perspective
Erik Thunnissen et al.
LUNG CANCER (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
Birgit G. Skov et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Liting Guo et al.
JOURNAL OF CANCER (2017)
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens
Jonas J. Heymann et al.
CANCER CYTOPATHOLOGY (2017)
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R. Hui et al.
ANNALS OF ONCOLOGY (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Proficiency testing in immunohistochemistry-experiences from Nordic Immunohistochemical Quality Control (NordiQC)
Mogens Vyberg et al.
VIRCHOWS ARCHIV (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
J. F. Novotny et al.
ANNALS OF ONCOLOGY (2016)
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions
Safiya Karim et al.
FUTURE ONCOLOGY (2016)
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation
Ian A. Cree et al.
HISTOPATHOLOGY (2016)
ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen
Merdol Ibrahim et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
Steffen Filskov Sorensen et al.
TRANSLATIONAL ONCOLOGY (2016)
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Marius Ilie et al.
VIRCHOWS ARCHIV (2016)
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
Lorena Incorvaia et al.
ONCOTARGET (2016)
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Charlotte Roach et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson
CANCER BIOLOGY & MEDICINE (2016)
PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age
Anita Midha et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
New clinical advances in immunotherapy for the treatment of solid tumours
Valentina A. Zavala et al.
IMMUNOLOGY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
Edward B. Garon
SEMINARS IN ONCOLOGY (2015)
Targeting the tumor microenvironment to enhance antitumor immune responses
Kevin Van der Jeught et al.
Oncotarget (2015)
Novel Immune Check-Point Regulators in Tolerance Maintenance
Yanxia Guo et al.
Frontiers in Immunology (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
Standardization of Diagnostic Immunohistochemistry Literature Review and Geisinger Experience
Fan Lin et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment
Chiara Camisaschi et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2014)
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
Yang Zhang et al.
ONCOTARGETS AND THERAPY (2014)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
Inflammatory cytokines as a third signal for T cell activation
Julie M. Curtsinger et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
分享论文
